Trodelvy plus Keytruda effective for aggressive breast cancer type: Gilead Sciences Ruchika Sharma23 April 2025 10:30 AM ISTFoster City: Gilead Sciences, Inc. has announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that...
Gilead Sciences earns USFDA Breakthrough Therapy Designation for lung cancer treatment Trodelvy Ruchika Sharma19 Dec 2024 1:30 PM ISTFoster City: Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy...
Gilead withdraws bladder cancer drug Trodelvy in US Farhat Nasim20 Oct 2024 11:00 AM ISTBengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients with a type of bladder...
Gilead Sciences Trodelvy, Keytruda combo study demonstrates promising clinical activity in first-line Metastatic Non-Small Cell Lung Cancer Ruchika Sharma12 Sept 2023 2:30 PM ISTFoster City: Gilead Sciences, Inc. has announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy...
Gilead Sciences Trodelvy gets European Commission nod for pre-treated HR+/HER2- metastatic breast cancer Ruchika Sharma28 July 2023 4:30 PM ISTFoster City: Gilead Sciences, Inc. has announced that the European Commission (EC) approved Trodelvy (sacituzumab govitecan) as a monotherapy for...
Gilead Sciences gets CHMP positive opinion for Trodelvy in pre-treated HR+/HER2- metastatic breast cancer Ruchika Sharma24 Jun 2023 4:30 PM ISTFoster City: Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Gilead Sciences secures USFDA okay for Trodelvy for pre-treated HR+/HER2- Metastatic Breast Cancer Ruchika Sharma4 Feb 2023 11:37 AM ISTTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
EMA validates marketing authorization application for Trodelvy for Pre-treated HR+/HER2- Metastatic Breast Cancer: Gilead Sciences Ruchika Sharma5 Jan 2023 4:30 PM ISTTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
Gilead Sciences Trodelvy under USFDA priority review for adult patients with pretreated metastatic breast cancer Ruchika Sharma14 Oct 2022 2:30 PM ISTTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
Gilead Sciences drug Trodelvy modestly delays breast cancer progression in late-stage trial Ruchika Sharma6 Jun 2022 4:09 PM ISTWall Street analysts, on average, expect annual sales of the drug will top $2 billion 2026, according to Refinitiv.
Doctor launches campaign for crowdfunding Rs 1 crore for mother's cancer treatment Medical Dialogues Bureau5 Jan 2022 9:45 AM ISTThe SN Medical College junior resident, Dr Anjali Gupta, has also requested Prime Minister Narendra Modi and Chief Minister Yogi Adityanath for help.
Gilead Sciences, Merck collaborate to evaluate Trodelvy in combo with Keytruda Ruchika Sharma31 Oct 2021 9:30 AM ISTFoster City: Gilead Sciences, Inc. has recently announced the company has entered into a clinical trial collaboration and supply agreement with Merck...
